eLife APC and Open Access: Current Fee, Reviewed Preprints, and the Real Cost Decision

The official eLife submission page currently states two points that should drive the whole decision:

1. papers sent for review are published as Reviewed Preprints

1. the current publication fee is $3,750

That is a meaningful change from the older eLife model and from older fee figures still floating around online. The old shorthand that eLife costs around $2,000 or £2,000 is now stale. The current official page says $3,750, and it also says the fee is waived for anyone who cannot afford to pay.

The practical implication is simple:

• if the editors decline the paper before review, you pay nothing

• if the paper enters review, you are paying for transparent peer review and reviewed-preprint publication

• after that point, there is no traditional hidden accept-reject gate

At most APC pages, the cost question is attached to an acceptance decision:

• paper accepted

• author chooses open access

• fee paid at acceptance or production

At eLife, the sequence is different:

• paper passes editorial screening

• paper enters peer review

• fee is triggered

• the paper plus reviews are published as a Reviewed Preprint

That means the fee is not a price for prestige signaling in the normal journal sense. It is a price for a specific publishing process.

If the authors actually want transparent review, that can be a reasonable trade. If they mainly want a conventional accepted-paper outcome, the fee is harder to justify because the process is solving a different problem.

The Scopus-style numbers above are useful only as visibility signals. They do not restore the old prestige shorthand that came with an active JCR listing. That is why eLife remains easy to misread.

The useful year-over-year read is that the last listed JIF was down from 8.7 in 2021 to 7.6 in 2022, and then eLife became ineligible for a JIF after Web of Science put it on hold, because eLife kept its publishing model rather than change it. So the fee question in 2026 is not "am I paying for a journal with a live JIF?" It is "am I paying for a transparent-review venue that still has real scientific visibility?"

Across eLife-bound manuscripts, the APC decision usually goes wrong in three ways.

Authors treat the fee as cheap access to a respected biology logo. That is the wrong framing. The fee is tied to a reviewed-preprint model with public reviews. If the coauthors or institution still think in conventional acceptance language, the mismatch shows up later.

Teams budget for the fee but do not budget for the public record. At eLife, the paper's first serious critique becomes part of the visible publication history. When the evidence package is still soft, that can create a worse strategic outcome than a normal private rejection.

The manuscript is good science but weak eLife-model fit. Papers that would be better served by a standard selective journal often arrive at eLife because the authors like the price or the open-science brand. That is usually not enough. The model fit matters as much as the science fit.

That is why the fee decision should come after the model-fit decision, not before it.

The fee is easier to justify when:

• the authors deliberately want transparent review and public assessment

• the field reads reviewed preprints sensibly

• the team values speed and openness more than traditional journal shorthand

• the paper is strong enough to benefit from public review rather than be exposed by it

• the fee is covered by a grant or institutional budget rather than personal funds

The fee is harder to justify when:

• the authors still need a classic accepted-paper signal

• promotion or grant workflows still rely heavily on active JCR listings

• the team is uncomfortable with public reviews attached to the paper

• the manuscript is still one serious revision away from being ready for public scrutiny

The current eLife fee is $3,750, and the journal says it will waive the fee for authors who cannot afford it. On price alone, that is not an unreasonable number for a visible life-sciences venue.

But this is not a normal APC page. The real question is whether you want what eLife is actually selling:

• transparent peer review

• public editorial assessment

• a reviewed-preprint publication path

• visibility without a current JCR impact factor

If the answer is yes, the fee can make sense. If the answer is no, the paper probably belongs somewhere else even if the price looks attractive.

Before paying for that model, an eLife submission readiness check is the fastest way to decide whether the manuscript is actually ready for a public-review outcome.